Despite conventional and new therapies for the treatment of chronic GVHD (cGVHD), this syndrome continues to account for significant morbidity and mortality after allogeneic hematopoietic stem cell transplantation. 
herpesvirus infection. 4, 9 It has been suggested that four features of cGVHD at presentation predict poor outcome: progressive presentation of disease, concomitant thrombocytopenia, lichenoid skin or mucose-membrane histology and liver dysfunction. 10, 11 Despite the improved survival in patients with established cGVHD due to the conventional, new approved and investigational therapies, many patients continue to have poor clinical function. None of the present therapies for cGVHD are successful in the majority of patients. These unsatisfactory results have led some authors to conclude that 'there is no convincingly effective therapy for cGVHD'. 12 Over the past 10 years alternative methods for the treatment of established cGVHD have been studied. This review focuses on the results of conventional and new alternative treatments of cGVHD.
Clinical presentation of cGVHD
Chronic GVHD, in general, occurs more than 100 days after BMT. Clinical characteristics include features similar to autoimmune diseases and the disease may involve various organs including skin, mouth, liver, eyes, intestines, esophagus, lungs and other sites. 13 Chronic GVHD may develop as an extension of acute GVHD (progressive onset), after resolution of acute GVHD (quiescent onset), or without preceding acute GVHD (de novo onset). Chronic GVHD is categorized as either limited (localized skin and/or hepatic involvement) or extensive (diffuse skin and/or multi-organ involvement); the latter is associated with a worse prognosis. 14 This staging system was proposed by the Seattle group using data for 20 patients in an era of limited therapy for GVHD prevention (mainly with methotrexate). 13 It is unknown whether the Seattle groups of organ involvements are the most predictive in the modern era of allogeneic transplantation using more effective therapies for GVHD prevention. In our practice we use a staging system according to clinical severity (mild, moderate and severe) of involved organs, in addition to the Seattle classification.
Pathophysiology of cGVHD
Histopathologically cGVHD is characterized by a marked increase in collagen deposition in the target organs and a
Bone Marrow Transplantation lack of T lymphocyte infiltration. 15 Pathological changes such as skin and pulmonary fibrosis, decreased esophageal motility and increased autoantibody production to thyroid, muscle and erythrocytes in patients with cGVHD suggest that cGVHD has clinical symptomatology similar to autoimmune diseases, especially, to scleroderma. Because of its similarities to autoimmune disease, the pathogenesis of cGVHD has been thought to differ from acute GVHD. Decreasing thymic function with age and, especially, in transplanted patients as a result of combined pretransplant chemoradiotherapy and acute GVHD, may result in decreased negative selection or the extrathymic generation of T lymphocytes with subsequent increase of peripheral autoreactive T lymphocytes. 16, 17 Autoreactive T lymphocytes are an important effector mechanism with increased ␥-interferon production playing a central role in the increased collagen deposition that is the central histopathologic feature of cGVHD. 18 
Conventional treatment of cGVHD
Without treatment less than 20% of patients with extensive chronic GVHD survive with Karnofsky performance scores у70%. 19 It has been shown that prednisone or antithymocyte globulin, given later in the course of disease do not improve survival or reduce permanent disability. In the first randomized study conducted on 164 previously untreated patients, the Seattle group showed that treatment with prednisone alone results in fewer infections and better survival (61% at 5 years) than prednisolone and azathioprine (survival at 5 years 47%) in standard risk cGVHD. Patients with a platelet count Ͻ100 000 l (defined as high risk group) received only prednisone with a survival of 26% at 5 years. 20 In a non-randomized study alternating daily cyclosporine and prednisone improved survival in 61 highrisk cGVHD patients (51% in 40 previously untreated patients and 67% in 21 patients failed prior prednisone therapy). 21 In another randomized study the combination of cyclosporine plus prednisone (CsA + PRED) therapy was superior to prednisone alone with respect to a high survival (80% vs 71%) due to a lower non-relapse and infectious mortality in the combination treatment group. 22 In a recent large randomized study from Seattle in standard risk patients with extensive cGVHD (n = 305) the outcome of treatment after 9 months of therapy was better in the combination cyclosporine plus prednisone arm than in the prednisone arm (46% complete remission and 42% treatment failure vs 33% and 48%, respectively; P = 0.032 and P = 0.031, respectively). In high risk patients (n = 202) randomized to receive CsA or CsA + PRED the complete remission rate and failure rate were 18% and 57% vs 33% and 46%, respectively.
23 By 1 year post transplant 65% of standard risk and 81% of high risk patients developed infections. Multivariate analysis in standard risk patients found that prednisone treatment, progressive onset, number of disease sites and baseline bilirubin were independent predictors for treatment failure, while in high risk patients CsA treatment, progressive onset, age and bilirubin were significant factors for failure. Results of salvage treatment in patients not achieving complete response to prednisone containing initial treatments with cyclosporine alternating with prednisone or azathioprine or PUVA or thalidomide showed low complete response rates (14-30%) and high nonrelapse mortality (14-29%). 24 In all groups, however, the non-relapse mortality rate remains high.
Most of these patients were adults. To our knowledge there are no published large reports of using conventional treatment in pediatric patients with cGVHD. In our experience children treated with conventional therapy have a high complete remission rate compared with the results reported in the literature in adult patients (unpublished data).
Thalidomide (N-phatalidoglutarimide)
This drug was initially used as a sedative, but it was later found to have immunosuppressive effects. 25 Because of its teratogenic side-effects it became unavailable for a long period, but has achieved renewed interest in the treatment of cGVHD. The immunosuppressive and anti-inflammatory properties of thalidomide include impairment of neutrophil phagocytosis and chemotaxis and reduction in antibody production in response to antigenic stimulation, with increased T suppressor cells and reduced T helper cells and inhibition of TNF-␣. 26, 27, 28 Vogelsang et al 29 demonstrated thalidomide to be safe and effective in 23 patients with cGVHD refractory to conventional treatment and in 21 patients with high risk cGVHD: complete responses were observed in seven (30%) of 23 patients given this drug as salvage treatment and in seven (33%) of 21 patients given this agent as primary therapy. A partial response was observed in 12 patients, and no response in 18. Sixteen patients died primarily as a result of cGVHD. The median duration of therapy was 240 days (range 2-700). In this trial sedation and constipation were the major side-effects and four patients discontinued their medication for peripheral neuropathy. Heney et al 30 who treated six patients with refractory cGVHD reported similar results: four patients had a dramatic response and one a partial response. In two patients peripheral neuropathy was observed. Encouraging results were obtained in children treated with thalidomide for refractory and/or high risk extensive cGVHD. 31 In this study six (42%) of 14 patients given thalidomide had complete clinical responses, four (28%) had a partial response and four (28%) failed treatment. The best responders had predominantly mucocutaneous involvement by cGVHD and most of them had a quiescent form of disease. Treatment duration ranged from 1.3 to 102 months and non-relapse mortality was 28%. Sedation was the major side-effect and two patients developed peripheral neuropathy.
Parker et al 32 in a phase II study used thalidomide as salvage therapy to determine the efficacy in 80 patients with refractory cGVHD who failed to respond to prednisone or prednisone and cyclosporine. Sixteen patients (20%) had a sustained response, nine with complete remission and seven with a partial response. Among the 16 patients who responded to thalidomide the median duration of therapy was 16 months (range 0.3-4.5 years). Most responses were in patients with isolated mouth or liver cGVHD and skin involvement without severe sclerodermatous manifestations. Forty-three of the 80 (53%) treated patients are alive. Non-relapse mortality was 46%, primarily as a result of cGVHD. All patients were maintained on prednisone and cyclosporine when started on thalidomide. Twenty-nine patients (36%) had thalidomide discontinued because of side-effects, which included sedation, constipation or neuritis. Additionally, they observed two side-effects, namely skin rashes and neutropenia, not previously reported during thalidomide use for cGVHD treatment, which resulted in discontinuation of drug in five and in 10 patients, respectively.
These results confirm that thalidomide has some activity against cGVHD. Whether early introduction of thalidomide can improve efficacy in the treatment of cGVHD or whether thalidomide should really be used as first-line treatment of cGVHD, is still undefined.
Photochemotherapy (PUVA)
Several studies have reported that ultraviolet A irradiation after oral treatment with 8-methoxypsoralen (PUVA), can improve various skin diseases thought to be related to immunologic disorders, such as psoriasis as well as cutaneous cGVHD. 33, 34 PUVA may be acting in cGVHD by directly affecting the effector lymphocytes, by blocking antigen presentation and co-stimulatory signals (IL-1) and/or induction of clonal anergy by affected Langerhans cells. 35 Vogelsang et al 35 used PUVA therapy in 40 patients with lichenoid cGVHD limited to skin and oral mucosa (14 patients), oral mucosa (four patients) and systemic multiorgan (22 patients) disease. Most of the patients had refractory cGVHD. Patients were treated three or four times a week with the total number of PUVA treatments ranging from two to 92. In all but one patient, PUVA was given while the patients were on immunosuppressive treatment. Overall, 31 of 40 patients (77.5%) responded; 16 patients (40%) achieved a complete response and 15 patients (37%) a partial response. Despite improvement of cutaneous lesions in patients with systemic multiorgan cGVHD, 13 of 22 patients (59%) died of GVHD-related complications which indicate that PUVA lacks a systemic effect on established cGVHD. None of the three patients treated for sclerodermoid cGVHD responded to PUVA therapy. Six of seven patients with oral manifestations of cGVHD treated with intraoral PUVA responded (87%) with complete response in four patients (57%). The most important shortterm side-effect in these series was severe phototoxicity of the skin (PUVA burn with blistering and marked erythema of the skin) observed in three patients. Overall, treatment was interrupted in seven patients (17%) for phototoxicity. One patient developed basal cell carcinoma 7 years after PUVA therapy which is the most important long-term sideeffect of PUVA. 36, 37 Similar results were reported in patients treated with PUVA for cGVHD in a limited number of patients. 33, 34, [38] [39] [40] 
Extracorporeal photochemotherapy (ECP)
This is a new apheresis technique used for the treatment of severe cutaneous T cell lymphoma and a variety of autoimmune diseases and organ transplant rejections, with encouraging results. [41] [42] [43] Recent reports indicated that ECP may be used successfully in selected, refractory cases of early lichen-planus-like and late sclerodermatous cGVHD. [44] [45] [46] ECP is performed by treating lymphocytes, removed from the patients by leukapheresis, with 8-methoxypsoralen and UVA irradiation in an extracorporeal system with subsequent reinfusion of treated cells into the patient without producing side-effects in other organs. Although the precise mechanisms of action of ECP remain unclear, clinical and experimental data indicated that a specific 'vaccination effect' occurs after infusion of photoinactivated pathogenic T cells mediated by CD8-positive T cells without general immunosuppression. 47 A limited number of patients are reported to have been treated with ECP as therapy for skin and systemic multiorgan cGVHD, with encouraging results. 48 Complete or partial resolution of gastrointestinal tract involvement (7/8 patients), ocular gland involvement (3/4 patients) and bronchiolitis obliterans involvement has been observed. As treatment-related side-effects, 14 patients had increased red cell and platelet transfusion requirement, four had catheter-related sepsis, two developed severe chills and one patient had tetanic cramping.
FK506
FK506 (tacrolimus) is a new, potent immunosuppressive drug similar to cyclosporine that blocks T cell activation. However, in contrast to cyclosporine, FK506 does not affect natural killer cell function. 52 Currently, FK506 is used as the primary immunosuppressant against graft rejection in organ transplant patients. In the allogeneic BMT setting this drug has mainly been used for prevention and therapy of acute GVHD. 53, 54 The published experience using FK506 as therapy for cGVHD was limited to a single case, 55 until a recent report by Kanamaru et al. 56 In this study, 26 patients with localized and/or extensive cGVHD were evaluated for response to FK506. The response was good in 10 patients, marked in two, poor in eight and absent in six patients. These authors showed that eye, skin and gut involvement responded better to FK506 treatment than did liver, mouth and lung disease. As expected, renal toxicity (53%), nausea and vomiting (30%) were significant sideeffects of the drug. They noted a correlation of toxicity with whole blood FK506 concentration, and most of the adverse effects subsided soon after withdrawal of this drug.
Total lymphoid irradiation (TLI)
Total lymphoid irradiation has been shown to be an effective immunosuppressive tool in animals 57 as well as in human autoimmune diseases. 58 TLI has been reported to be effective in a limited number of patients with refractory cGVHD. 59, 60 Fung et al 61 used low-dose thoracoabdominal irradiation (TAI) (100cGy) in 12 patients with cGVHD who failed initial treatment with cyclosporine and corticosteroids. After TAI, five patients achieved a significant clinical response with good to complete amelioration of disease, three patients had a minor response, three patients no response and one died of multiorgan failure. Currently, 11 patients are alive. Recently, Devergie et al 62 reported 38 patients with extensive cGVHD treated with low-dose (1 Gy) TLI. After a median of 2 months post TLI, major to complete improvement was observed in 20 out of 38 patients (52%). Twelve patients died, three patients were not evaluable and three patients are alive with cGVHD. Toxicity of the procedure was minimal with a transient decrease in blood counts. They recommended the use of early TLI for patients with progressive cGVHD unresponsive to conventional therapy.
Mycophenolate mofetil (MMF)
MMF is a potent immunosuppressive agent that selectively inhibits proliferation of T and B lymphocytes. It is successfully used for the prevention of acute rejection in primary cadaveric renal allograft recipients. 63 Published clinical experiences using MMF to treat cGVHD were limited, until a recent series of reports. Recently, Basara et al 64 reported 17 patients with acute GVHD and seven patients with cGVHD treated with MMF. In the cGVHD group six patients had limited and one extensive disease. Patients received MMF at a dose of 250 mg four times orally with a subsequent dose increase to 2 g per day, along with lowdose prednisolone. Only three patients with limited cGVHD had an improvement, while the patient with extensive cGVHD worsened with MMF therapy. The most common adverse hematologic events of MMF were leukopenia, anemia and thrombocytopenia. Results of using MMF as salvage treatment in 17 out of 22 evaluable patients with cGVHD who failed primary corticosteroid therapy showed low complete response (11%), 41% partial response and a high (47%) treatment failure rate. 65 Similar results have been reported by other authors after using MMF for refractory cGVHD as salvage treatment. 66 Therapy with MMF was associated with reversible neutropenia and gastrointestinal disturbances in some patients.
Clofazimine
Clofazimine is an antimycobacterial agent that has been used extensively in the treatment of leprosy and mycobacterium avium infections. 67 It has also been used for the treatment of some autoimmune diseases. 68 In a recent study, Lee et al 69 reported treatment results of 22 patients with cGVHD with clofazimine. There were six patients with limited and 16 patients with extensive cGVHD. All but two patients were receiving immunosuppressive therapy with cyclosporine and/or steroids when clofazimine was started. Treatment courses lasted 7 to 835 days. Over 50% of patients with skin involvement, flexion contractures, or oral manifestations achieved complete or partial responses. Seven of 22 patients (32%) were able to reduce other immunosuppressive medications. Non-relapse mortality was observed in five patients (22%); three of these patients were off therapy. Gastrointestinal side-effects occurred in eight patients (36%) and hyperpigmentation was noted in 12 patients (55%). The authors concluded that clofazimine is safe and has encouraging efficacy, particularly in patients with sclerodermatous skin, joint, or oral involvement.
Etretinate
Etretinate is a synthetic vitamin A derivative (retinoid derivate) that has been used in the treatment of several dermatologic conditions such as psoriasis, scleroderma, mycosis fungoides and Sezary syndrome. 70 Recently, Marcellus et al 71 administered etretinate orally to 32 patients with refractory sclerodermatous cGVHD with a median of 30 months history of disease. Most patients had failed to respond to three or more immunosuppressive agents before etretinate treatment was started. After 3 months of therapy among 27 patients evaluable for response, 20 showed improvement (74%) including softening of the skin, flattening of cutaneous lesions, increased range of motion, and performance status. Four patients (14%) had no response and three patients (11%) had progression of their sclerosis. The most important side-effects were skin breakdown and/or ulceration leading to discontinuation of treatment in six patients (18%). Xerosis, cheilitis, pruritus, transient hyperglyceridemia and hypercholesterolemia, eye irritation and thinning of the hair also occurred, but did not necessitate interruption of the therapy.
Ursodeoxycholic acid
Ursodeoxycholic acid (UDCA) has been given to patients with primary biliary cirrhosis, a disease similar to cGVHD, leading to improvement in disease manifestations. 72, 73 The mechanisms by which UDCA exerts its protective effect on the liver are not well understood. It has been suggested that in patients with primary cirrhosis, UDCA may work by an immune-mediated mechanism because UDCA therapy is associated with a reduction in class I HLA antigen expression on hepatocytes which could block immunemediated hepatocellular necrosis. 74 Fried et al 75 reported 13 patients treated with UDCA for refractory cGVHD of the liver. After 6 weeks treatment, while the doses of immunosuppressive agents remained constant, therapy with UDCA resulted in improvement in serum biochemical markers of cholestasis. Overall the drug was well tolerated. After discontinuation of UDCA therapy, 11 patients were followed for 6 additional weeks and all patients showed worsening in liver function test results. These authors suggested that further investigation is needed to evaluate the long-term effects of UDCA therapy.
Penicillamine
Summerfield et al 76 reported a patient who was treated with penicillamine for refractory (to corticosteroids and azathioprine) sclerodermatous cGVHD. After treatment with penicillamine, skin ulcers and joint contractures resolved completely. This report and reports of using penicillamine in refractory autoimmune diseases such as systemic sclerosis and rheumatoid arthritis may be sufficient justification for further studies.
Cyclophenile
Cyclophenile is a distant relation of oestrogen. It has been used for systemic sclerosis with success in some cases. Lönnqvist and co-workers 77 used cyclophenile in nine adult patients with sclerotic cGVHD with encouraging results.
Halofunginone
Because increased collagen deposition is the principal histopathological feature of cGVHD, halofunginone, a plant alkaloid that inhibits type I collagen synthesis, has been evaluated in a murine model of cGVHD. 78 This drug was given daily to mice 3 days after hematopoietic stem cell transplantation. An absence of increased cutaneous collagen disposition and the prevention of dermal thickening were observed. Such therapy may have a role in the treatment of human cGVHD.
Nedocromil sodium
It has been suggested that mast cells, playing a key role in allergic reactions, may also have a role in chronic inflammatory processes which often result in fibrosis as seen in some autoimmune diseases. Massive mast cell degranulation has been observed in the connective tissues of mice with cGVHD. 79 Nedocromil sodium, as a mast cell stabilizer, has been used in the murine model of cGVHD with amelioration of skin lesions. 80 Thus, therapies directed specifically at stabilization of mast cells may have a therapeutic benefit in cGVHD.
Prophylaxis against infection
There is increased susceptibility to bacterial, fungal and viral infections in patients with cGVHD due to both cGVHD and its treatment. Infections are a major cause of morbidity and mortality in these patients. Late pulmonary infection is more frequent in patients with cGVHD (50%) compared with those without cGVHD (21%). 81 The use of prophylactic trimethoprim/sulphamethoxazole has been effective in reducing the incidence of interstitial pneumonitis, 20 and other infections 82 in patients with cGVHD. There is a high incidence of reactivation of latent viruses, especially members of the herpes group which requires prolonged preemptive antiviral therapy with acyclovir. In the Bone Marrow Transplantation presence of cGVHD immune defects involving both cellular and humoral immunity lead to poor secondary immune responses and failure of interaction between T helper and B cells. 83 Thus, in patients with cGVHD the efficacy of vaccines is likely to be severely reduced and live vaccines are potentially unsafe. It has been suggested that in patients with cGVHD, functional asplenism may contribute to the increased incidence of pneumococcal sepsis. 84 Life-long prophylactic penicillin V (200 mg twice a day orally) is recommended for patients with cGVHD and splenectomized patients.
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Prevention of chronic graft-versus-host disease
There is slow if any progress in preventing cGVHD. Because acute GVHD is a powerful predictor of cGVHD, combination immunosuppression therapies for prophylaxis of acute GVHD may decrease the incidence of cGVHD. It has been shown that cyclosporine plus methotrexate are superior to cyclosporine or methotrexate alone, and cyclosporine plus methotrexate plus steroids are superior to cyclosporine plus methotrexate. 4, 87, 88 Long-term cyclosporine extended up to 12 months after BMT may decrease the incidence of cGVHD. 4, 89 In vivo ablation of alloreactive donor T cells after allogeneic hematopoietic transplantation could significantly contribute to preventing and treating GVHD. The use of donor cells expressing a 'suicide' gene such as the thymidine kinase gene of the herpes simplex virus 1 (HS-tk) has the potential for achieving such a goal. Long-lasting circulation of gene-modified cells as well as ganciclovir-induced decreases in circulating HS-tk expressing donor T cells (TkTC) has been documented. 90 Recently, Bonini et al 91 reported their experience using donor TkTC for treatment of patients with EBV-related lymphomas. Three patients developed GVHD after infusion of donor TkTC. Ganciclovir treatment resulted in complete response and the disappearance of circulating gene-modified cells in the two patients with acute GVHD while a partial response was achieved in the patient with chronic GVHD.
Conclusion
With conventional treatment, which usually includes corticosteroids alone or their combination with cyclosporine or azathioprine, about 50% of adult patients with cGVHD achieve a complete remission. Overall, this treatment is well tolerated. The most important complications of this treatment are infections and side-effects of steroids. Many of the new agents discussed here have been used as salvage treatment for cGVHD along with conventional immunosuppressive medications. Thus, it is difficult to define the role of these agents in the treatment of cGVHD without additional immunosuppression and randomized trials are necessary.
